Cost-effectiveness analysis of maximum androgen blockade for Japanese men with advanced prostate cancer

Shuzo Nishimura, Yoichi Arai, Michiyuki Usami, Hiroshi Kanetake, Seiji Naito, Hideyuki Akaza

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


Like other countries, Japan is facing the problem of rising medical costs associated with aging of the population, and therefore the cost-effectiveness of medicines has become increasingly important. Maximum androgen blockade (MAB) therapy, which is being widely used for advanced prostate cancer, has proved useful in clinical studies but it requires the additional use of an anti-androgen in contrast with luteinizing hormone releasing hormone agonist (LHRHa) monotherapy, raising a concern about the increase medical costs. Thus, based on the results of a Japanese Phase III study of bicalutamide we performed a cost-effectiveness analysis. We constructed a Markov model to express the changes in prognosis following MAB therapy and LHRHa monotherapy for advanced prostate cancer and the cost and effectiveness (survival) were simulated. As a result, the expected costs of MAB therapy and LHRHa monotherapy were 5,240,000 yen and 3,660,000 yen, respectively, with expected survival durations of 7.45 and 6.44 years. The incremental cost-effectiveness ratio for MAB therapy was 1,560,000 yen/life-year saved, lower than the established threshold (6,000,000 yen/life-year saved), and a sensitivity analysis confirmed the robustness of this result. Therefore, the incremental cost of bicalutamide was considered worth it in view of the therapeutic effect, suggesting that MAB therapy is a highly cost-effective therapy.

Original languageEnglish
Pages (from-to)589-595
Number of pages7
JournalGan to kagaku ryoho. Cancer & chemotherapy
Issue number4
Publication statusPublished - 2007 Apr

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Cost-effectiveness analysis of maximum androgen blockade for Japanese men with advanced prostate cancer'. Together they form a unique fingerprint.

Cite this